Latest

Telomir Pharmaceuticals closes $5.6 million PIPE as DeJoria adds to stake

The financing backs Telomir's Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer after the FDA cleared the drug's IND.

SEC filing